Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Clin Biochem ; 109-110: 23-27, 2022.
Article in English | MEDLINE | ID: mdl-36041500

ABSTRACT

OBJECTIVES: Flat shaped glucose curves (FC) during oral glucose tolerance test (OGTT) in pregnant women (PW) are a not uncommon finding. We aimed to define the FC incidence in a large PW cohort and to describe the status of insulin and C-peptide secretion in women with FC when compared with a well-matched control group. METHODS: 1050 PW performing OGTT for gestational diabetes screening were enrolled. An increase <6 % in plasma glucose (PG) during OGTT defined a FC. Serum samples for measuring insulin and C-peptide were also obtained. RESULTS: 61 (5.8 %) women showed a FC. 60 of them, paired to a group of 60 no-FC women matched for age, body mass index and gestational age, were further investigated. C-peptide and insulin concentrations were significantly lower (P < 0.001) in FC in both 1-h and 2-h OGTT samples. When incremental area under the curves (AUC) normalized to PG were estimated, only AUCinsulin remained however significantly lower. The insulin sensitivity index was higher in FC. CONCLUSIONS: PW with FC showed a hypersensitivity to insulin with normal ß-cell function. Moreover, a delayed glucose absorption could be hypothesised because of the slight but continuously increasing shape of insulin curve found in FC group. Both phenomena could occur in parallel and contribute to FC.


Subject(s)
Diabetes, Gestational , Insulin Resistance , Female , Pregnancy , Humans , Male , Glucose Tolerance Test , Insulin Secretion , Blood Glucose , C-Peptide , Pregnant Women , Incidence , Insulin Resistance/physiology , Insulin , Diabetes, Gestational/diagnosis , Glucose
2.
Clin Chem Lab Med ; 60(11): 1706-1718, 2022 10 26.
Article in English | MEDLINE | ID: mdl-35998662

ABSTRACT

Appropriateness in Laboratory Medicine has been the object of various types of interventions. From published experiences, it is now clear that to effectively manage the laboratory test demand it is recommended to activate evidence-based preventative strategies stopping inappropriate requests before they can reach the laboratory. To guarantee appropriate laboratory test utilization, healthcare institutions should implement and optimize a computerized provider order entry (CPOE), exploiting the potential of electronic requesting as "enabling factor" for reinforcing appropriateness and sustaining its effects over time. In our academic institution, over the last 15 years, our medical laboratory has enforced various interventions to improve test appropriateness, all directly or indirectly based on CPOE use. The following types of intervention were implemented: (1) applying specific recommendations supported by monitoring by CPOE as well as a continuous consultation with clinicians (tumour markers); (2) removing outdated tests and avoiding redundant duplications (cardiac markers, pancreatic enzymes); (3) order restraints to selected wards and gating policy (procalcitonin, B-type natriuretic peptide, homocysteine); (4) reflex testing (bilirubin fractions, free prostate-specific antigen, aminotransferases, magnesium in hypocalcemia); and (5) minimum retesting interval (D-Dimer, vitamin B12, C-reactive protein, γ-glutamyltranspeptidase). In this paper, we reviewed these interventions and summarized their outcomes primarily related to the changes in total test volumes and cost savings, without neglecting patient safety. Our experience confirmed that laboratory professionals have an irreplaceable role as "stewards" in designing, implementing, evaluating, and maintaining interventions focused to improving test appropriateness.


Subject(s)
Diagnostic Tests, Routine , Unnecessary Procedures , Academic Medical Centers , Bilirubin , C-Reactive Protein , Homocysteine , Humans , Magnesium , Natriuretic Peptide, Brain , Procalcitonin , Prostate-Specific Antigen , Transaminases , Vitamins
3.
J Endod ; 48(11): 1421-1427, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35987386

ABSTRACT

INTRODUCTION: The aim of this study was to evaluate torsional, dynamic, and static cyclic fatigue resistance of the reciprocating One RECI (OR; Micromega, Besançon, France), WaveOne Gold (WOG; Dentsply Maillefer, Ballaigues, Switzerland), rotary One Curve (OC, MicroMega), and ProTaper Next X2 (PTN X2; Dentsply Sirona, Charlotte, NC) instruments. METHODS: A total of 120 OR (n = 30), WOG (n = 30), OC (n = 30), and PTN X2 (n = 30) nickel-titanium instruments were used. Torque and rotation angle until failure under static torsion loading were measured according to ISO 3630-1. Static and dynamic fatigue resistance was measured as the time to fracture in an artificial stainless steel canal with a 60° angle and 5-mm radius of curvature at intracanal temperature. The results were analyzed with 1-way analysis of variance and the post hoc Tukey test. The alpha-type error was set at 5%. Fracture instruments from torsion and fatigue tests were examined with a scanning electron microscope. RESULTS: OR showed higher static fatigue resistance and rotation angle at fracture than WOG, OC, and PTN X2 (P < .05). WOG exhibited higher torsional resistance than the others (P < .05). The cyclic fatigue tests in dynamic mode had higher TTF than static for the PTN X2 and WOG groups (P < .05). In the dynamic tests, OR and WOG showed higher TTF than OC and PTN X2 (P < .05). CONCLUSIONS: Under these experimental conditions, One RECI exhibited suitable mechanical properties with the highest cyclic fatigue resistance and angle of rotation among the tested instruments.


Subject(s)
Nickel , Titanium , Stainless Steel , Equipment Failure , Equipment Design , Gold , Root Canal Preparation , Dental Instruments , Materials Testing , Stress, Mechanical
4.
Clin Chem Lab Med ; 60(9): 1342-1349, 2022 08 26.
Article in English | MEDLINE | ID: mdl-35785546

ABSTRACT

In medical laboratories, the appropriateness challenge directly revolves around the laboratory test and its proper selection, data analysis, and result reporting. However, laboratories have also a role in the appropriate management of those phases of total testing process (TTP) that traditionally are not under their direct control. So that, the laboratory obligation to act along the entire TTP is now widely accepted in order to achieve better care management. Because of the large number of variables involved in the overall TTP structure, it is difficult to monitor appropriateness in real time. However, it is possible to retrospectively reconstruct the body of the clinical process involved in the management of a specific laboratory test to track key passages that may be defective or incomplete in terms of appropriateness. Here we proposed an appropriateness check-list scheme along the TTP chain to be potentially applied to any laboratory test. This scheme consists of a series of questions that healthcare professionals should answer to achieve laboratory test appropriateness. In the system, even a single lacking answer may compromise the integrity of all appropriateness evaluation process as the inability to answer may involve a significant deviation from the optimal trajectory, which compromise the test appropriateness and the quality of subsequent steps. Using two examples of the check-list application, we showed that the proposed instrument may offer an objective help to avoid inappropriate use of laboratory tests in an integrated way involving both laboratory professionals and user clinicians.


Subject(s)
Laboratories , Humans , Retrospective Studies
6.
Clin Chem Lab Med ; 60(1): 135-142, 2022 01 26.
Article in English | MEDLINE | ID: mdl-34687597

ABSTRACT

OBJECTIVES: Previous studies reported lipase elevations in serum of COVID-19 patients trying to establish a causal link between SARS-CoV-2 infection and pancreatic damage. However, the degree and prevalence of hyperlipasemia was not uniform across studies. METHODS: We retrospectively evaluated 1,092 hospitalized patients with COVID-19 and at least one available lipase result. The number and frequency of patients with lipase above the upper reference limit (URL), >3 URL, and >6 URL were estimated. Correlations between lipase values and other biomarkers of organ or tissue damage were performed to identify possible extra-pancreatic sources of lipase release. The potential prognostic role of lipase to predict death and intensive care unit (ICU) admission during hospitalization was also evaluated. RESULTS: Lipase was >URL in 344 (31.5%) of COVID-19 patients. Among them, 65 (5.9%) and 25 (2.3%) had a peak lipase >3 URL and >6 URL, respectively. In the latter group, three patients had acute pancreatitis of gallstone or drug-induced etiology. In others, the etiology of lipase elevations appeared multifactorial and could not be directly related to SARS-CoV-2 infection. No correlation was found between lipase and other tested biomarkers of organ and tissue damage. Lipase concentrations were not different between survivors and non-survivors; however, lipase was significantly increased (p<0.001) in patients admitted to the ICU, even if the odds ratio for lipase as predictor of ICU admission was not significant. CONCLUSIONS: Lipase was elevated in ∼1/3 of COVID-19 patients, but the clinical significance of this finding is unclear and irrelevant to patient prognosis during hospitalization.


Subject(s)
COVID-19 , Lipase/blood , Acute Disease , Biomarkers/blood , COVID-19/blood , COVID-19/diagnosis , Humans , Intensive Care Units , Retrospective Studies
9.
Clin Chem ; 66(5): 667-675, 2020 05 01.
Article in English | MEDLINE | ID: mdl-32353141

ABSTRACT

BACKGROUND: The measurement of neuron-specific enolase (NSE) in serum is frequently requested for diagnosis, risk stratification, and treatment monitoring of neuroblastoma (NB) in the pediatric population. However, authoritative clinical practice guidelines advise about the poor diagnostic performance of NSE. CONTENT: We critically appraised the available literature evaluating the diagnostic and prognostic value of NSE in the management of NB, paying special attention to the definition of appropriate threshold levels. In addition, we discuss the interfering conditions causing artifactual increases of NSE concentrations in serum and potentially influencing the clinical evaluation of patients with suspected NB. SUMMARY: No definitive evidence supports the use of serum NSE for diagnosis and monitoring of NB. The risk of obtaining false-positive NSE results associated with confounders (e.g., sample hemolysis) and other pathophysiologic conditions (e.g., inflammation) is remarkable and hampers the diagnostic value of this test. NSE may be helpful to define the risk of death of patients with NB, mainly in the advanced stages of disease. However, further studies validating currently marketed immunoassays and defining threshold values useful for this scope are warranted.


Subject(s)
Biomarkers, Tumor , Neuroblastoma , Child , Humans , Neuroblastoma/diagnosis , Neuroblastoma/therapy , Phosphopyruvate Hydratase , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...